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Background: Comorbid mental health problems have been shown to have an adverse effect on the quality of life
of people with common eye disorders. This study aims to assess whether symptoms of anxiety and/or depression
are more prevalent in people with age-related macular degeneration (AMD) than in people without this condition.
Methods: A systematic search of electronic databases (Medline, CINAHL, EMBASE, PsycINFO) from inception to
February 2012 was conducted to identify studies of AMD populations which measured symptoms of anxiety and/or
depression. Reference checking of relevant articles was also performed. Data on the study setting, prevalence and
how anxiety and depression were measured were extracted from the papers. Critical appraisal was performed using
the Critical Appraisal Skills Programme (CASP) tools.
Results: A total of 16 papers were included in the review, from an original search result of 597. The prevalence
estimates, taken from nine cross-sectional and cohort studies, ranged from 15.7%-44% for depressive symptoms and
9.6%-30.1% for anxiety symptoms in people with AMD. The seven case–control studies found that people with
AMD were more likely to experience symptoms of depression compared with those without AMD, but not more
likely to experience symptoms of anxiety.
Conclusions: Overall, the evidence suggests that symptoms of depression are more prevalent amongst AMD
populations than anxiety symptoms. The heterogeneity of the studies included in this review means that it is
difficult to draw strong conclusions as to the true estimates of depression and anxiety symptoms in AMD
populations and prevented formal meta-analysis. Further research which specifies clinical anxiety and gives clear
definitions as to the type of AMD being investigated is required.
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Age-related macular degeneration (AMD) is a condition
affecting between 20 to 25 million people worldwide and
is the most common form of visual impairment in
people aged over 50 in the United Kingdom [1,2]. Symp-
toms of AMD, including difficulty in reading text, recog-
nising faces and completing general house work [3], may
directly lead to increased disability which could in turn
lead to an increase in symptoms of depression and anx-
iety [4]. Depression and anxiety could be also be exacer-
bated by the social isolation caused by AMD or by the* Correspondence: c.d.mallen@keele.ac.uk
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reproduction in any medium, provided the orneed to give up work [5]. Ranibizumab is currently the
only on license drug available in the UK to treat neovas-
cular AMD [6,7], and an association of poor vision and
increased mental health issues may be an additional fac-
tor that could be used when justifying this high cost
treatment.
Studies of clinical mood disorders have prevalence es-
timates of between 8-12% in the general UK population
[8] and up to 13% [9] in UK primary care populations.
The number of people with non-clinical mood symp-
toms is likely to be much higher. The prevalence of psy-
chiatric symptoms is likely to be different in community
compared to clinical settings, with prevalence rates gen-
erally increasing through primary, secondary and tertiaryl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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cant adverse effect on quality of life in a number of
physical conditions [10-12], including AMD [3,13-17],
meaning that its detection and management represents a
priority for clinicians and patients alike. A previous sys-
tematic review [16] of quality of life in people with
AMD provides a brief summary of the evidence for anx-
iety and depressive symptoms but the present review up-
dates this evidence and reviews it in more detail.
The aim of this study is to assess whether symptoms
of anxiety and/or depression are more prevalent in
people with AMD than in those without.
Methods
The PRISMA guidelines [18] were followed for this re-
view and the sections below are set out according to
these guidelines.
Eligibility criteria
Papers which reported the prevalence of anxiety, depres-
sion or both in adults aged 18 years and above with AMD
(cross-sectional or cohort studies), or reported anxiety
and/or depression scores of both AMD sufferers and a
comparison group (case–control studies), were included.
Any setting was permitted (primary care, secondary care
or general population), although the search was limited to
English language papers. Clinical trials were excluded as
they include highly selected populations.
Information sources
The following databases were searched from inception
to February 2012: CINAHL, EMBASE, PsycINFO and
Medline. The reference lists of relevant papers were also
searched for further papers.
Search
The search was developed by a group with expertise in
clinical medicine, psychology and systematic reviewing
and included terms for anxiety, depression and AMD.
Search strategy for electronic databases
“worry” OR “panic” OR “anxiety” OR “Nervousness”
OR “concern” OR “apprehension” OR “angst” OR “fear”
OR “disquiet” OR “fretfulness” OR “unease” OR
“despair” OR “sadness” OR “misery” OR “hopelessness”
OR “melancholy” OR “dejection” OR “depression” OR
“unhappiness”
AND
“macular” OR “degeneration” OR “AMD” OR “ARMD”.
Study selection
After title scanning, abstracts from the electronic data-
bases thought to be relevant were retrieved for closer in-
spection. If deemed to meet the inclusion criteria, thefull text of the article was located. The reference lists of
all full text papers from the electronic search were
scanned for further relevant articles, which were proc-
essed in the same way as those retrieved from the elec-
tronic search.
Data collection process
Information from all papers found to meet the inclusion
criteria was entered into a data extraction table created
using Microsoft Word. Details included the study set-
ting, the prevalence and the method of assessment of
anxiety and/or depression. Data was independently ex-
tracted by two reviewers to ensure accuracy.
Risk of bias in individual studies
All included studies were subjected to methodological crit-
ical appraisal using the Critical Appraisal Skills Programme
(CASP). These tools contain a series of questions to assess
how effectively the participants in each of the studies were
selected, the main results of the study, the reliability of
these results and whether the results can be used to benefit
the local population. CASP was chosen as it is a compre-
hensive and detailed appraisal tool suitable for assessing
the studies included in the review. Different versions of the
tool are tailored to different study designs. A score is gen-
erated by summing the number of positive responses to
each question, with a higher number indicating higher
quality. Each article was assessed by three independent re-
viewers (SRD, MBG, RY) and any differences in score were
resolved by discussion with a 4th reviewer (CDM). The
total CASP score each paper received is included in the
data extraction table (Additional file 1).
Summary measures
The prevalence of anxiety and/or depression was ex-
tracted from the cross-sectional and cohort studies, and
the p-value indicating whether anxiety and/or depression
were statistically significantly higher in the AMD popu-
lation compared to the control group was taken from
the case–control studies.
Risk of bias across studies
Non-English language papers could not be included due
to lack of translation resources, but the number of papers
excluded for this reason was included in the study flow-
chart (Figure 1) so the potential impact of this could be
examined. It is also possible that studies that did not find
a high prevalence of anxiety or depression are less likely to
be published than those that did find a high prevalence.
Results
Study selection
Of the 597 electronic search results, 30 full papers were
retrieved. The reference lists of each of these papers
Papers retrieved from CINAHL, EMBASE, 
PSYCH INFO, MEDLINE
(597)




Not original research: (4)
Foreign Language: (1) 
Review: (1)
Not looking at anxiety or 
depression: (9)
Clinical trial: (2)




Not looking at anxiety/depression: 
(9)
Not primary study: (3)
Foreign Language: (1)
Clinical trial: (1)
Further papers identified from 
reference lists as potentially relevant 
(25)
Papers excluded (24):
No relevant statistics: (9) 
Not specifically about 
anxiety/depression: (5)
Not primary study: (2)
Excludes depression/anxiety: (3) 
No comparator: (1)
Clinical trial (5)
References from review papers 
thought to be potentially relevant (0)
Reference from other sources 
(citation checking, conferences, 
experts) (1)
Total Number of Papers:
14 + 1 + 1 = 16
Figure 1 Flowchart for how articles were chosen for inclusion.
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possibly relevant. Of the original 30 studies, 14 were
relevant and one of the 25 later identified was relevant.
A final paper was identified from an expert in the litera-
ture, giving a total of 16 papers (see Figure 1).
Study characteristics
The detailed results of the review can be found in
Additional file 1. Out of the 16 studies included (includ-
ing between 51 and 65,404 participants), nine were con-
ducted in the United States, one in Canada, one in
Australia and one was a multi-country study involving
France, Germany and Italy. Four of the remaining stud-
ies were part of a different multi-country study; one of
these papers contained the overall results for Canada,France, Germany, Spain and the UK [19] and the indi-
vidual results from the UK [20], Spain [21] and Canada
[3] make up the remaining three papers. Three of the
papers were cohort studies [13,14,22], seven were case–
control studies [3,19-21,23-25] and the remaining six
were cross-sectional surveys [15,26-30].
Measures of anxiety and depression
Anxiety and depression were measured using a number
of different tools, the most popular being the Hospital
Anxiety and Depression Scale (HADS) [3,19-21,28] and
the Centre for Epidemiological Studies- Depression scale
(CES-D) [13-15,27,30]. The HADS is a self-administered
questionnaire consisting of a 14 items, seven of which
relate to anxiety and seven to depression [31]. A score of
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anxious, those with a score from eight - 10 are defined as
‘possible’ depression or anxiety and a score of 11 or over
was classified as ‘probable’ depression or anxiety. The
CES-D [32,33] records the frequency and severity of de-
pressive symptoms over the preceding week via a 20 item
questionnaire. Each item is scored on a scale from 0 (less
than 2 days duration) to 3 (5–7 days) inclusive, and a
score of 16 or over indicates major depression.
Other tools used in the included papers were the
Structured Clinical Interview (SCID-IV) for DSM-IV
[26], the Geriatric Depression Scale (GDS) [25,29], the
Goldberg Anxiety and Depression scale (GAD) [23], the
International Classification of Diseases (ICD-9-CM) [24]
and the Patient Health Questionnaire (PHQ) [22]. The
SCID-IV is a standardised tool for diagnosing clinical
depression and can diagnose both major and minor de-
pression. The ICD-9-CM is more of a classification tool
than a clinical instrument, but the study that reported
use of this tool used it in conjunction with another tool,
the Charlston Comorbidity Index (CCI). However it is
not clear from the papers exactly how depression was
measured using these instruments. The GDS [34] com-
prises a series of 30 yes/no questions about the patient’s
feelings over the previous week. A score more than 15
(+/−6) indicates mild depression and a score over 23
(+/−5) major depression. The GAD [35] contains 18
questions, 9 each for anxiety and depression. Each of the
items is scored by asking the patient to answer ‘yes’ or
‘no to a number of questions. Four questions for both
anxiety and depression are used as ‘screening’ questions,
and one or more positive responses to these questions
leads to the interviewer asking the remaining questions.
The higher a patient’s score, the higher the chance of
them having clinically significant depression or anxiety.
Finally, the PHQ [36] is a 10-item self-report question-
naire that asks patients to rate how often particular
problems have bothered them over the preceding two
weeks. At least four positive responses to any of the
items are indicative of a depressive disorder, with a score
of 20 or above indicating severe depression.
Risk of bias within studies
Overall the papers scored highly on the CASP tools, with
participant groups being recruited from acceptable popu-
lations. The studies used previously validated measures to
collect data on anxiety and depression, although it was
not always clear whether the measures had been validated
within the study population. Not all studies specified cut-
offs for major depression and none specified cut-offs for
clinical anxiety, suggesting that precise prevalence esti-
mates may not be available. The majority of included stud-
ies adjusted for potential confounding variables which
could have an effect on the prevalence estimates obtained.Results of individual studies
All 16 included studies examined depression, with all of
the articles consistently finding that the prevalence of de-
pressive symptoms in adults with AMD was higher than
in those without. The prevalence estimates provided
ranged from 15.7%-44% in the cross-sectional and cohort
studies and the case–control studies reported a significantly
(p < 0.05) higher prevalence of depression in participants
with AMD compared to non-AMD sufferers. Different
methods were used to diagnose depression and studies in-
cluded different subtypes of AMD, meaning a formal meta-
analysis was not possible.
Depressive symptoms in neovascular AMD
Five publications studied depression in neovascular AMD
specifically [3,19-21,28]. Of these, one study [28] was
cross-sectional and the remaining four were case–control
studies. All studies recruited their participants from eye
clinics or specialist retina centres. All of the studies except
one [28] compared their AMD sample depression preva-
lence rates with those of a community sample who did
not suffer from any ocular pathology. The final study re-
ported that they compared the findings from the AMD
group with that of “a comparable German population” but
did not give information as to the details of this popula-
tion. The cross-sectional study reported a prevalence rate
of 17.9% and the case–control studies all reported that
depression was significantly (p < 0.05) more prevalent in
the AMD populations. Three studies [19,20,28] looked at
the relationship between AMD severity and depressive
symptoms. Two [19,28] found that depressive symptoms
worsen as neovascular AMD severity increases.
Depressive symptoms in non-specified AMD
The majority of studies did not specify whether they
were examining neovascular or non-neovascular AMD.
These studies recruited their participants mostly from
eye clinics [13-15,23,25,27] or community settings
[22,24,26,30], although one [29] did not state a setting.
Six studies [13,14,23-26] stated that they compared their
depression prevalence rates in AMD populations with
community populations with no eye pathologies. One
study [30] compared early and late AMD populations.
For the remaining studies it was difficult to identify
the sample they were comparing their findings in AMD
populations against.
Cohort studies by Rovner et al. [13-15,22,27] reported
prevalence estimates for depression of between 20% [22]
and 43% [15]. Although the same data and method of
measuring depression was utilised in all of the studies by
this group, different figures of baseline depression preva-
lence were stated in the two articles that specified major
depression (23.5% [13] and 27.5% [27]). The former
study [13] found the prevalence to be much higher than
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care clinics, but included people with a much lower vis-
ual acuity (VA). One article [14] that used the same data
as in a previous study [13] but a different method of cal-
culating depression showed a higher prevalence (33%),
suggesting the way in which depression is measured can
affect study findings.
The case–control studies [23-25] that included a
clinical cut-off found depression to be significantly
(p < 0.05) higher in the AMD population than in the
control group.
Two cross-sectional studies reported estimates of 26%
[29] and 32.5% [26] although this latter estimate was
lower when looking only at major depression (7.3%). A
final cross-sectional study [30] reported prevalence esti-
mates for depressive symptoms of 15.7% and 17.2% for
early and late AMD respectively.
Few studies looked at whether severity of depressive
symptoms was related to severity of AMD. Of those
that did [14,27,29], all found that increasing AMD se-
verity was related to an increase in depressive symp-
toms. A final study which compared the prevalence of
depressive symptoms in those with early and late AMD
[30] found no statistically significant difference between
the two groups.
Anxiety symptoms in neovascular AMD
Four case–control studies examined anxiety in neovas-
cular AMD, all of which recruited their participants
from eye clinics. Three [3,20,21] reported no difference
between those with AMD and those without. One [19]
reported a prevalence which was significantly (p < 0.05)
higher than the prevalence in a control population re-
cruited from GP clinics. A cross-sectional study [28]
found a prevalence estimate of 30.1% for anxiety. Of
those that looked at the relationship between neovascu-
lar AMD severity and anxiety symptoms [19,20,28], none
found a relationship.
Anxiety symptoms in non-specified AMD
One cross-sectional study [29] compared AMD patients
with severe visual impairment with those with minimal
impairment, and found no statistically significant differ-
ence (p = .13). Like the studies of neovascular AMD, this
study also failed to find a relationship between an in-
crease in anxiety symptoms and AMD severity.
Risk of bias across studies
Only two papers were excluded for not being available
in English (see Figure 1), suggesting that this is unlikely
to have resulted in language bias. It is also possible that
studies where a low prevalence of mental health symp-
toms was found were not published, leading to publica-
tion bias. However, a number of electronic databaseswere searched and reference lists were checked for pub-
lished and unpublished literature in an attempt to locate
all possible studies that had calculated prevalence esti-
mates for AMD populations.
Discussion
Summary of evidence
The aim of this review was to assess the prevalence of
symptoms of anxiety and depression in people with
AMD. The results indicate that depressive symptoms are
more common in people with AMD than in non-AMD
populations. Overall, despite few studies looking into the
association, there does appear to be a relationship be-
tween increasing AMD severity and higher prevalence of
depression. Many of the studies did not differentiate be-
tween neovascular and non-neovascular AMD, and
those that did found that both types of AMD were asso-
ciated with depressive symptoms.
The results from the studies examining anxiety symp-
toms generally show that anxiety symptoms have a low
prevalence in AMD populations. The two studies that
did report a high prevalence [19,28] were large studies
but one [19] did not report any cut-offs for their anxiety
measure, so it was not clear if the anxiety measured was
‘clinically significant’. Overall, no study found a relation-
ship between increasing AMD severity and anxiety
prevalence in either the neovascular or non-specified
AMD studies.
A number of issues with the included studies may help
explain the range of different prevalence estimates
found. The definition and measure of anxiety or depres-
sion used in each study and the type of AMD being in-
vestigated varied, making the results difficult to interpret
collectively. Some studies compared their results to pop-
ulations without AMD but did not actually include a
control group within their study, which may mean that
the comparison group is not representative. For ex-
ample, the studies by Rovner et al. [13] and Casten et al.
[15] provided prevalence estimates for depressive symp-
toms from older community populations (1-3% and 7.1%
respectively), and Augustin et al. [28] stated that the
prevalence of depression was higher than in a compar-
able German sample but did not provide the estimates
for this sample or details of the population.
A final issue is that of causality, which cannot be
established due to the design of the studies. Future ob-
servational studies could include an assessment of prior
psychological distress, perhaps through a medical re-
cords review, in order to establish whether symptoms of
anxiety or depression existed before the onset of AMD.
Limitations
Many studies did not specify the type of AMD they were
investigating, and from the small number of studies that
Dawson et al. BMC Ophthalmology 2014, 14:78 Page 6 of 7
http://www.biomedcentral.com/1471-2415/14/78looked specifically at neovascular AMD it is not possible
to say whether the prevalence of symptoms of anxiety or
depression are different in this particular form of the
condition. The differentiation between the subtypes
could be important due to the different time courses
and treatments of each. The amount of time since diag-
nosis and how rapidly, and if, vision deteriorated was
not mentioned in any of the studies. Ranibizumab is li-
censed for the treatment of neovascular AMD and a
high success rate of maintaining patients’ current visual
acuity has been reported [37]. The anticipation of vision
deteriorating, how rapidly it has already deteriorated, the
length of time since diagnosis and the possibility of
available treatments are all important factors which
could affect patients’ psychologically. The patient’s per-
ception of how their vision loss impacts on their life is
important to assess; a recent paper [38] found that self-
reported vision loss was associated with depression
where objective vision loss as assessed by an ophthal-
mologist was not. Further studies looking at AMD sub-
types, the effect of length of time since diagnosis, and
the treatment options offered or received to help im-
prove patients’ mental health would be useful in helping
decide when to consider psychological diagnoses and the
most effective time to offer interventions.
While studies of RCTs would possibly have provided
more clearly defined groups of AMD sufferers, they also
contain more highly selected populations and tend to
screen out co-morbidities such as symptoms of anxiety
or depression, meaning that we may not have seen the
true extent of these symptoms if we had included this
type of study.
The CASP tool may not be appropriate to use with
cross-sectional studies. However, the authors are not
aware of any critical appraisal tool that is designed spe-
cifically for use with cross-sectional studies and it was
decided that this tool would allow standardisation of
the information collected and allow comparison across
the studies. Also, the CASP tool provides an overall
score for each study, which may not accurately com-
pare study quality [5]. However, giving a summary score
is helpful when gaining consensus between reviewers
with respect to overall methodological quality and a de-
tailed discussion of the critical appraisal can be found
in the Results section.
Finally, many of the papers considered for inclusion in
the review were located through additional searches and
not through the electronic search strategy. However, the
additional searches only located two more relevant pa-
pers, suggesting that the original search was adequate.
Implications for practice
The evidence presented in this review supports evidence
from previous studies that symptoms of depression arecommon in people with AMD. This indicates screening
for depression should be considered, perhaps as part of
routine follow-up, and appropriate resources allocated
for this purpose. Further studies are needed to assess
whether AMD sufferers would benefit from intervention
options such as cognitive-behavioural therapy (CBT) or
treatment with medication. The few studies that looked
at whether severity of depressive symptoms was related
to severity of AMD found that increasing AMD severity
was related to an increase in depressive symptoms.
Therefore interventions could be targeted at those with
the most severe form of the condition. Again, more
studies are required to differentiate between those with
neovascular and non-neovascular subtypes as currently
it is unknown whether depressive symptoms are more
prevalent in one type of AMD. Since this review found
little evidence for an increased risk of anxiety symp-
toms in AMD sufferers, anxiety screening is unlikely to
be of benefit.
Conclusions
The current literature examining the prevalence of
symptoms of depression and anxiety in people with
AMD suggests that depressive symptoms are prevalent
in AMD populations compared with non-AMD popula-
tions, but anxiety symptoms are not. The studies in-
cluded in the review scored well on the CASP tools,
suggesting good methodological quality. However, many
did not specify the type of AMD being assessed and dif-
ferent definitions of anxiety and depression were used,
making the generalisability of the results difficult to as-
sess. Future work would benefit from clearly specifying
the type of AMD being studied, including a control or
comparator group to allow for comparison of the preva-
lence of anxiety and/or depression between AMD and
non-AMD populations, and the use of tools which give a
clear cut-off for clinical anxiety and depression.
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Additional file 1: Table S1. Data extraction of all included studies.
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